Triple antithrombotic therapy and dual therapy – What is the evidence base?-Reference-Cited by-同舟云学术

Triple antithrombotic therapy and dual therapy – What is the evidence base?

Published:2022-02-16 Issue:7 Volume:88 Page:3009-3012
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Essa Hani¹²^ORCID,Sankaranarayanan Rajiv¹²,Walker Lauren³^ORCID

Affiliation:

1. Department of Cardiology, Aintree University Hospital Liverpool University Hospitals NHS Foundation Trust Longmoor lane Liverpool L9 7AL United Kingdom

2. Liverpool Centre for Cardiovascular Science University of Liverpool, Liverpool Heart & Chest Hospital Liverpool UK

3. Clinical Pharmacology and Therapeutics University of Liverpool Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15257

Reference25 articles.

1. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

2. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

3. Patients with atrial fibrillation and coronary artery disease – Double trouble

4. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observation of the Therapeutic Effect of Wild Plantain on Patients with CYP2C19 Gene In-termediate Metabolic Phenotype during Percutaneous Coronary Intervention;Advances in Clinical Medicine;2023